SATURDAY 17 SEPTEMBER

12.15-14.00 Satellite symposia
C.01 | Consequences of cognitive dysfunction in depression Hall F2
  Educational financial support provided by H. Lundbeck A/S

14.00-14.45 ECNP patient session E5.01 | Hosted by the Expert Platform on Mental Health Hall K

14.45-16.30 Satellite symposia
C.02 | THINC-it®: a tool to evaluate cognitive dysfunction in depression Hall F2
  Educational financial support provided by H. Lundbeck A/S
C.03 | Advances in long-acting antipsychotic therapy – neurobiological, clinical and functional perspectives Hall E1
  Educational financial support provided by Janssen Pharmaceutica NV

16.50-18.30 Symposia & Educational update session
PR S.01 | Life on the brink: social stress and psychopathology Hall D
TR S.02 | Alzheimer-type dementia in people with Down syndrome Hall E1
CR S.03 | Understanding cannabis addiction: challenges, opportunities and new horizons Hall E2
CT S.04 | Biomarkers in bipolar disorders – from clinical need to clinical application Hall F1
PR S.05 | Brain cytochrome p450 enzymes genetic polymorphisms role in affective disorders and drug responses Hall K
EN E.01 | EPA educational session – First episode psychosis beyond the dopamine paradigm Hall F2

18.45-20.00 Keynote session KL.01 | Mood disorders and creativity Hall D

20.00-21.30 Welcome reception Entrance Hall

07.45-08.45 Brainstorming sessions
BS.01 | Psychostimulant/methylphenidate effects and underlying mechanisms in ADHD and healthy subjects Room -2.16
BS.02 | Future perspectives for treatment of anxiety disorders Room -2.31
BS.03 | The importance of behavioural tasks for the translational study of psychopathology Room -2.32

09.00-10.40 Symposia & Educational update session
PR S.06 | Novel mechanistic insights into mood disorders Hall D
TR S.07 | Psychedelics: new insights into brain function Hall E1
CR S.08 | Neuroactive steroids in neuroregeneration and neurodegeneration: a translational approach Hall E2
CT S.09 | Negative symptoms of schizophrenia: pathophysiological mechanisms and relevance to functional outcome Hall F1
CR S.10 | TNM symposium – Novel strategies towards targeted interventions in PTSD Hall K
EN E.02 | Assessment and treatment of sleep problems/disorders Hall F2

09.00-11.00 Expert science exchange CE.01 | Cognitive dysfunction in depression Room -2.91
Organised by H. Lundbeck A/S

10.40-11.15 Poster viewing Poster area / Travel award ceremony Poster area (podium) / Coffee break Poster area and exhibition
11.15-12.00 Plenary lecture PL.01 | Functional genomic and transcripational networks in Autism Spectrum Disorder (ASD) Hall D
12.00-14.00 Lunch Poster area and exhibition
12.15-13.45 Poster session Poster area
12.15-12.45 Rapid-fire poster session Poster area (podium)
13.00-13.15 Poster award ceremony Poster area (podium)
13.15-14.45 Career development session CD.01 | Building your CV Poster area (podium)
Top paper sessions TP.01 | Highlights in child and adolescent disorders 2015-2016 Room -2.31
TP.02 | Highlights in Alzheimer’s disease 2015-2016 Room -2.32

14.00-14.45 Plenary lecture PL.02 | ECNP Neuropsychopharmacology Award lecture – Rediscovering drug discovery in bipolar disorder Hall D

14.45-15.00 Coffee break Poster area and exhibition

15.00-16.40 Symposia & Educational update session
PR S.11 | Metabotropic glutamate receptors in addiction disorders: from glutamate hypothesis to clinical relevance Hall D
TR S.12 | Junior Scientist symposium - Emerging targets for improved control of psychiatric disorders Hall E1
CR S.13 | New findings in autism research: the EU-AIMS study Hall E2
CT S.14 | Improving antidepressant treatment outcome mechanisms, moderators and innovative therapeutic strategies Hall F1
CT S.15 | Inflammation in psychosis: diagnosis and treatment Hall K
EN E.03 | Novel treatment approaches for eating disorders Hall F2

17.15-19.00 Satellite symposia
C.04 | Treatment paradigms and importance of outcome dimensions in schizophrenia – patient and physician outlooks Hall F2
  Educational financial support provided by Otsuka Pharmaceutical Europe Ltd. & H. Lundbeck A/S
C.05 | From clinical to functional remission in depression: how big is the gap? Hall K
  Educational financial support provided by Servier

SUNDAY 18 SEPTEMBER

09.00-11.00 Expert science exchange CE.01 | Cognitive dysfunction in depression Room -2.91
Organised by H. Lundbeck A/S

10.40-11.15 Poster viewing Poster area / Travel award ceremony Poster area (podium) / Coffee break Poster area and exhibition
11.15-12.00 Plenary lecture PL.01 | Functional genomic and transcripational networks in Autism Spectrum Disorder (ASD) Hall D
12.00-14.00 Lunch Poster area and exhibition
12.15-13.45 Poster session Poster area
12.15-12.45 Rapid-fire poster session Poster area (podium)
13.00-13.15 Poster award ceremony Poster area (podium)
13.15-14.45 Career development session CD.01 | Building your CV Poster area (podium)
Top paper sessions TP.01 | Highlights in child and adolescent disorders 2015-2016 Room -2.31
TP.02 | Highlights in Alzheimer’s disease 2015-2016 Room -2.32

14.00-14.45 Plenary lecture PL.02 | ECNP Neuropsychopharmacology Award lecture – Rediscovering drug discovery in bipolar disorder Hall D

14.45-15.00 Coffee break Poster area and exhibition

15.00-16.40 Symposia & Educational update session
PR S.11 | Metabotropic glutamate receptors in addiction disorders: from glutamate hypothesis to clinical relevance Hall D
TR S.12 | Junior Scientist symposium - Emerging targets for improved control of psychiatric disorders Hall E1
CR S.13 | New findings in autism research: the EU-AIMS study Hall E2
CT S.14 | Improving antidepressant treatment outcome mechanisms, moderators and innovative therapeutic strategies Hall F1
CT S.15 | Inflammation in psychosis: diagnosis and treatment Hall K
EN E.03 | Novel treatment approaches for eating disorders Hall F2

17.15-19.00 Satellite symposia
C.04 | Treatment paradigms and importance of outcome dimensions in schizophrenia – patient and physician outlooks Hall F2
  Educational financial support provided by Otsuka Pharmaceutical Europe Ltd. & H. Lundbeck A/S
C.05 | From clinical to functional remission in depression: how big is the gap? Hall K
  Educational financial support provided by Servier

CLINICAL TREATMENT TRACK  CLINICAL RESEARCH TRACK  TRANSITIONAL RESEARCH TRACK  PRECLINICAL RESEARCH TRACK  EDUCATIONAL TRACK
MONDAY 19 SEPTEMBER

07.45-08.45 Brainstorming sessions
B5.04 | Reassessment of the usefulness and safety of benzodiazepines (BZs) in the treatment of anxiety disorders  Room -2.16
B5.05 | Managing the attenuated psychosis syndrome  Room -2.31
B5.06 | Targeting the dopamine D3 receptor for clinical applications in several neuropsychiatric disorders  Room -2.32

09.00-17.00 Exhibition  Hall X2

09.00-10.40 Symposia & Educational update session
PR S.16 | Junior Scientist symposium - Novel pathophysiological insights into the causes of brain disorders  Hall D
TR S.17 | Long non-coding RNA: emerging roles in brain development and disease  Hall E1
CR S.18 | Neuroimaging biomarkers for psychiatric disorders in adolescence and young adulthood  Hall E2
CT S.19 | Obsessive-compulsive disorder clinical heterogeneity and innovative treatment approaches  Hall F1
ET S.20 | Regulatory update session – Strategies to prevent and slow the clinical decline in Alzheimer type dementia  Hall K

09.00-12.00 Plenary lecture  PL.03 | The role of stress and adverse life events in mood and anxiety disorders  Hall D

09.00-14.00 Lunch  Poster area and exhibition

10.40-11.15 Poster viewing  Poster area / Travel award ceremony  Poster area (podium) / Coffee break  Poster area and exhibition

10.40-11.00 Expert science exchange  CE.03 | Treatment choice in early stages of schizophrenia  Room -2.91

12.00-13.15 Poster session  Poster area

12.15-13.45 Poster award ceremony  Poster area (podium)

13.15-13.45 Career development session  CD.02 | How to write a grant application  Poster area (podium)

13.00-16.40 Symposia & Educational update session
PR S.21 | Genetic and epigenetic regulation of stress sensitivity from mouse to man relevance to anxiety and depression  Hall D
TR S.22 | Translational approaches in understanding hedonic eating and neuroplasticity  Hall E1
CR S.23 | Ecstasy, the love drug: acute effects of MDMA on psychosocial processes  Hall E2
CT S.24 | TNM symposium – Experimental medicine and brain disorders – the agenda for 2017 and beyond  Hall F1
CR S.25 | Emotion recognition in neurodegeneration  Hall K
ET S.20 | Bipolar – an update on clinical treatment and lithium mechanisms  Hall F2

14.00-16.40 Plenary lecture  PL.04 | Translational research in schizophrenia: towards therapy and prevention beyond dopamine antagonism  Hall D

14.45-15.00 Coffee break  Poster area and exhibition

15.00-16.40 Symposia & Educational update session
PR S.21 | Genetic and epigenetic regulation of stress sensitivity from mouse to man relevance to anxiety and depression  Hall D
TR S.22 | Translational approaches in understanding hedonic eating and neuroplasticity  Hall E1
CR S.23 | Ecstasy, the love drug: acute effects of MDMA on psychosocial processes  Hall E2
CT S.24 | TNM symposium – Experimental medicine and brain disorders – the agenda for 2017 and beyond  Hall F1
CR S.25 | Emotion recognition in neurodegeneration  Hall K
ET S.20 | Bipolar – an update on clinical treatment and lithium mechanisms  Hall F2

17.15-19.00 Satellite symposia
C.06 | Why do we need new treatments for major depression and schizophrenia?  Hall F2

C.07 | Atypical antipsychotics: recent research findings and applications to clinical practice  Hall E1

Organised by H. Lundbeck A/S & Otsuka Pharmaceutical

Educational financial support provided by Otsuka Pharmaceutical Development & Commercialization, Inc. & H. Lundbeck A/S

Educational financial support provided by Sunovion Pharmaceuticals and Sumitomo Dainippon Pharma
07.45-08.45 Brainstorming sessions
BS.07 | Computational modeling approaches to schizophrenia  Room -2.16
BS.08 | Anti-NMDA receptor in encephalitis and psychosis same fate? Room -2.31
BS.09 | Neuroimaging predictors of antidepressant response: just taking off or dead-end road? Room -2.32

09.00-17.00 Exhibition  Hall X2

09.00-10.40 Symposia & Educational update session
PR  S.26 | Stress and homeostasis: how chronic stress affects physiological processes  Hall D
TR  S.27 | The role of neuroinflammation in psychiatric and neurological diseases  Hall E1
CR  S.28 | Developmental aspects and top-down regulation in ADHD  Hall E2
CT  S.29 | Improving data reproducibility in neuropsychiatric research  Hall F1
TR  S.30 | Translational strategies to treat alcohol abuse/dependence and associated depression/anxiety comorbidities: focus on opioid dysregulation  Hall K
ET  E.06 | Treating suicidal behaviour  Hall F2

10.40-11.15 Poster viewing Poster area / Travel award ceremony Poster area (podium) / Coffee break Poster area and exhibition

11.15-12.00 Plenary lecture  PL.05 | Brain Prize plenary lecture – Behaviour-determined signalling in brain circuits understanding cognition and memory in health and disease  Hall D

12.00-14.00 Lunch Poster area and exhibition

12.00-14.00 Nomenclature session  NS.01 | Classification of psychotropics in your pocket – the NbN app  Hall F2

12.15-13.45 Poster session Poster area

12.15-12.45 Rapid-fire poster session Poster area (podium)

13.00-13.15 Poster award ceremony Poster area (podium)

13.15-13.45 Career development session  CD.03 | How to get published  Poster area (podium)

Top paper sessions  TP.05 | Highlights in mood disorders 2015-2016 Room -2.31
TP.06 | Highlights in psychotic disorders 2015-2016 Room -2.32

14.00-14.45 Plenary lecture  PL.06 | Physical and emotional pain: is there a difference?  Hall D

14.45-15.00 Coffee break Poster area and exhibition

15.00-16.40 Symposia & Educational update session
PR  S.31 | TNM symposium – Enhancing preclinical neuroscience data quality and its utility for drug discovery  Hall D
TR  S.32 | Translational models must reflect evolving concepts of psychosis from psychopathology to pathobiology  Hall E1
CR  S.33 | Phenotype-genotype interactions in developmental disorders  Hall E2
CT  S.34 | From neuroscience to evidence based psychological treatments  Hall F1
ET  S.35 | Biomarkers for diagnosis, endophenotype characterisation and treatment in stress-related psychiatric disorders  Hall K
ET  E.07 | Traumatic brain injury – a neuropsychiatric perspective  Hall F2